Rick Doblin
Rick Doblin, Ph.D., is the founder and president of the Multidisciplinary Association for Psychedelic Studies (MAPS), a nonprofit established in 1986 to advance evidence-based psychedelic therapy and end prohibition. MAPS incubated Lykos Therapeutics (formerly MAPS Public Benefit Corporation) which is leading drug development of MDMA-assisted therapy for PTSD.
- Psychedelic Science 2025 — June 16–20 at the Colorado Convention Center in Denver
- MAPS
- Ad choices
Raw Description
<p>Rick Doblin, Ph.D., is the founder and president of the Multidisciplinary Association for Psychedelic Studies (MAPS), a nonprofit established in 1986 to advance evidence-based psychedelic therapy and end prohibition. MAPS incubated Lykos Therapeutics (formerly MAPS Public Benefit Corporation) which is leading drug development of MDMA-assisted therapy for PTSD. </p> <p><br></p> <p>Learn more about Psychedelic Science 2025, June 16–20 at the Colorado Convention Center in Denver, at <a href="http://www.psychedelicscience.org/">www.psychedelicscience.org</a>, and visit <a href="http://www.maps.org/">www.maps.org</a> for information on MAPS</p><p> </p><p>Learn more about your ad choices. Visit <a href="https://podcastchoices.com/adchoices">podcastchoices.com/adchoices</a></p>
Show Notes
Rick Doblin
Rick Doblin, Ph.D., is the founder and president of the Multidisciplinary Association for Psychedelic Studies (MAPS), a nonprofit established in 1986 to advance evidence-based psychedelic therapy and end prohibition. MAPS incubated Lykos Therapeutics (formerly MAPS Public Benefit Corporation) which is leading drug development of MDMA-assisted therapy for PTSD.
- Psychedelic Science 2025 — June 16–20 at the Colorado Convention Center in Denver
- MAPS
- Ad choices
Raw Description
<p>Rick Doblin, Ph.D., is the founder and president of the Multidisciplinary Association for Psychedelic Studies (MAPS), a nonprofit established in 1986 to advance evidence-based psychedelic therapy and end prohibition. MAPS incubated Lykos Therapeutics (formerly MAPS Public Benefit Corporation) which is leading drug development of MDMA-assisted therapy for PTSD. </p> <p><br></p> <p>Learn more about Psychedelic Science 2025, June 16–20 at the Colorado Convention Center in Denver, at <a href="http://www.psychedelicscience.org/">www.psychedelicscience.org</a>, and visit <a href="http://www.maps.org/">www.maps.org</a> for information on MAPS</p><p> </p><p>Learn more about your ad choices. Visit <a href="https://podcastchoices.com/adchoices">podcastchoices.com/adchoices</a></p>
